Skip to main content
Clinical Trials/NCT03109496
NCT03109496
Completed
Not Applicable

Study of the Upper Respiratory Tract Microbiota and the Potential of Probiotics for the Treatment of Chronic Otitis Media With Effusion.

University Hospital, Antwerp1 site in 1 country82 target enrollmentApril 26, 2017

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Otitis Media With Effusion
Sponsor
University Hospital, Antwerp
Enrollment
82
Locations
1
Primary Endpoint
Microbiota differences between the healthy and diseased URT and middle ear space
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

This study analyses which bacteria are present in the middle ear space and adjacent upper respiratory tract niches in healthy people and in patients suffering from chronic otitis media with effusion (OME; glue ear). The aim is to identify and isolate bacteria that are more common and more abundant in healthy people and to evaluate their potential to protect against bacteria commonly involved in OME and other upper respiratory tract infections.

To this end, samples will be collected from both groups (healthy vs OME) and analysed through sequencing of the bacterial 16S gene. In addition, samples obtained from healthy participants will be cultivated to isolate bacteria of interest.

Registry
clinicaltrials.gov
Start Date
April 26, 2017
End Date
June 6, 2019
Last Updated
6 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Ethisch Comité, UZA

prof. dr. Olivier Vanderveken, MD, PhD

University Hospital, Antwerp

Eligibility Criteria

Inclusion Criteria

  • Controls: undergo a surgery that gives access to the middle ear space (at least 30 participants; e.g. cochlear implant recipients) or the adenoids.
  • OME patients: have fluid accumulation in the middle ear space for 3+ months and receive ventilation tubes. May also undergo adenoidectomy.

Exclusion Criteria

  • Acute upper respiratory tract infections (including acute otitis media)
  • Chronic upper respiratory tract infections (except OME in patient group)
  • URT malformations (e.g. as seen in people with Down Syndrome or cleft palate)
  • Cystic fibrosis
  • Autoimmune diseases or immunodeficiency
  • Pregnancy
  • Use of antibiotics or steroids 1 week before surgery

Outcomes

Primary Outcomes

Microbiota differences between the healthy and diseased URT and middle ear space

Time Frame: Appr. 4 years

The composition of the bacterial community will be determined through sequencing of the bacterial 16S gene and compared between the participant groups. Species over-represented in healthy participants will be investigated further.

Study Sites (1)

Loading locations...

Similar Trials